肿瘤细胞治疗研究
FRONTIER PAPERS
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR T-Treated T-cell Lymphoid Malignancies.
综合而言，这些发现表明，在 CD7 CAR-T 细胞疗法的选择压力下，克隆异质性和表观遗传可塑性共同驱动 T 细胞淋巴系统恶性肿瘤的抗原阴性复发。
A phase 1 feasibility trial of BE-CAR33, an "off-the-shelf" base-edited CAR33 T cell therapy for acute myeloid leukemia.
符合条件的参与者为年龄小于16岁的复发/难治性AML患者。
Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.
第17届癌症科学前沿（FCS）年会（2025）强调了多组学、计算生物学和祖先特异性基因组学的融合，以推进主动性癌症护理。
Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia.
自体第二代靶向CD7的CAR-T 细胞，表达抗CD7蛋白表达阻断剂以防止自我杀伤的同室相残，被输注给3例复发/难治性CD7+急性髓系白血病儿童/年轻成人患者，结果达到可测量残留病阴性。
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia
22例AML（n=13）和T-ALL（n=9）患者入组，中位年龄63岁（范围31-77）。
Correction: CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
Efficacy, Safety, and Kinetics of Naturally Selected Anti-CD7 CAR-T Cell Therapy in T-ALL/LBL With CNS Leukemia.
Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models.
降低化疗后的复发率仍是提高肿瘤治疗疗效的一大挑战。
TA-TMA occurring after sequential CD7 CAR-T cell therapy and allogeneic hematopoietic stem cell transplantation: a case report.
目前，CAR-T细胞治疗桥接异基因造血干细胞移植（allo-HSCT）已成为难治/复发性血液系统恶性肿瘤的关键治疗策略。
CAR T cells: the missing piece needed to improve outcomes for children with cancer?
B 细胞急性淋巴细胞白血病 (B-ALL) 是儿童期最常见的癌症。
MEMBER ACCOUNT
登录成功会直接打开下一页。
